Stock AFFYMAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Affymax, Inc. OTC Bulletin Board

Equities

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Affymax, Inc.
2014 Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer CI
2014 Affymax Seeks Acquisitions CI

Business Summary

Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

Sales per Business

USD in Million2012Weight2013Weight Delta
Collaboration
99.6 %
- - 1 99.6 % -
License and Royalty
0.4 %
- - 0 0.4 % -

Sales per region

USD in Million2012Weight2013Weight Delta
United States
100.0 %
94 100.0 % 1 100.0 % -98.55%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,490,095 37,490,095 ( 100.00 %) 0 100.00 %

Shareholders

NameEquities%Valuation
Yellowstone Partners LLC
0.0207 %
7,770 0.0207 % 8 $
Manulife Investment Management Ltd.
0.008685 %
3,256 0.008685 % 3 $
Delux Capital Group LLC
0.001675 %
628 0.001675 % 1 $
Integrity Asset Management LLC
0.001600 %
600 0.001600 % 1 $
AlphaStream Portfolios, Inc.
0.000453 %
170 0.000453 % 0 $
QS Legg Mason Global Asset Allocation LLC
0.000229 %
86 0.000229 % 0 $

Company contact information

Affymax, Inc.

600 Fifth Avenue Suite 2260

10020, New York

+

http://www.affymax.com
address Affymax, Inc.

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+34.20% 50.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.61% 42.82B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.03B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.82% 26.11B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.68% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.45% 13.05B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.09% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.06% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AFFY Stock
  4. Stock
  5. Company Affymax, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW